chloroquine has been researched along with Cytokine Release Syndrome in 15 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To verify the efficacy of glucocorticoids, chloroquine and vitamin A in the treatment of cytokine release syndrome (CRS), and to investigate the underlying mechanisms, based on network pharmacology." | 8.12 | Efficacy of glucocorticoids, chloroquine and vitamin A on cytokine release syndrome: a network pharmacology study. ( He, SQ; Wang, JX; Zhang, J; Zhu, JJ, 2022) |
| "Pharmacological treatment of cachexia consists mainly of progestagens and glucocorticosteroids." | 5.62 | Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. ( Czerw, A; Deptała, A; Kapala, P; Kiedrowska, M; Kiedrowski, M; Skoczynska, A, 2021) |
| "To verify the efficacy of glucocorticoids, chloroquine and vitamin A in the treatment of cytokine release syndrome (CRS), and to investigate the underlying mechanisms, based on network pharmacology." | 4.12 | Efficacy of glucocorticoids, chloroquine and vitamin A on cytokine release syndrome: a network pharmacology study. ( He, SQ; Wang, JX; Zhang, J; Zhu, JJ, 2022) |
| "Favipiravir has resulted in a higher viral clearance than remdesivir." | 2.72 | A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. ( Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M, 2021) |
| " Long-term use of hydroxychloroquine is the cornerstone in the treatment of several auto-immune disorders." | 2.66 | Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. ( Khuroo, MS, 2020) |
| "Pharmacological treatment of cachexia consists mainly of progestagens and glucocorticosteroids." | 1.62 | Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. ( Czerw, A; Deptała, A; Kapala, P; Kiedrowska, M; Kiedrowski, M; Skoczynska, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 15 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mendoza-Pinto, C | 1 |
| García-Carrasco, M | 1 |
| Munguía Realpozo, P | 1 |
| Méndez-Martínez, S | 1 |
| Ahmad, B | 1 |
| Ul Hassan, N | 1 |
| Sehar, B | 1 |
| Zeb, F | 1 |
| E Nayab, D | 1 |
| Siddiqui, FA | 1 |
| Zhang, J | 1 |
| Zhu, JJ | 1 |
| He, SQ | 1 |
| Wang, JX | 1 |
| Licciardi, F | 1 |
| Giani, T | 1 |
| Baldini, L | 1 |
| Favalli, EG | 1 |
| Caporali, R | 1 |
| Cimaz, R | 1 |
| Askanase, AD | 1 |
| Khalili, L | 1 |
| Buyon, JP | 1 |
| Kang, Y | 1 |
| Chen, T | 1 |
| Mui, D | 1 |
| Ferrari, V | 1 |
| Jagasia, D | 1 |
| Scherrer-Crosbie, M | 1 |
| Chen, Y | 1 |
| Han, Y | 1 |
| Lucchino, B | 1 |
| Di Franco, M | 1 |
| Conti, F | 1 |
| Iannaccone, G | 1 |
| Scacciavillani, R | 1 |
| Del Buono, MG | 1 |
| Camilli, M | 1 |
| Ronco, C | 1 |
| Lavie, CJ | 1 |
| Abbate, A | 1 |
| Crea, F | 1 |
| Massetti, M | 1 |
| Aspromonte, N | 1 |
| Oscanoa, TJ | 1 |
| Romero-Ortuno, R | 1 |
| Carvajal, A | 1 |
| Savarino, A | 1 |
| Khuroo, MS | 1 |
| Li, S | 1 |
| Liu, C | 1 |
| Guo, F | 1 |
| Taleb, SJ | 1 |
| Tong, M | 1 |
| Shang, D | 1 |
| Pimentel, J | 1 |
| Andersson, N | 1 |
| Kiedrowski, M | 1 |
| Kapala, P | 1 |
| Kiedrowska, M | 1 |
| Skoczynska, A | 1 |
| Czerw, A | 1 |
| Deptała, A | 1 |
| Bahadoram, M | 1 |
| Keikhaei, B | 1 |
| Saeedi-Boroujeni, A | 1 |
| Mahmoudian-Sani, MR | 1 |
| Kheirabadi, D | 1 |
| Haddad, F | 1 |
| Mousavi-Roknabadi, RS | 1 |
| Rezaeisadrabadi, M | 1 |
| Dehghan, H | 1 |
| Fazlzadeh, A | 1 |
10 reviews available for chloroquine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Therapeutic options for the management of severe COVID-19: A rheumatology perspective.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agents; Chloroquine; Combined | 2021 |
COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Juvenile; Beta | 2020 |
Cardiovascular manifestations and treatment considerations in COVID-19.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inh | 2020 |
Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Betacoronavirus; CCR5 Receptor Antagonis | 2020 |
A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
Topics: Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Anticoagulants; Antiviral Agents; Autopha | 2020 |
Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; | 2020 |
Traditional Chinese Medicine as Potential Therapy for COVID-19.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antiviral Agen | 2020 |
Chloroquine and its derivatives in the management of COVID-19: A scoping review
Topics: Antiviral Agents; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Compassionate Use Trials; | 2020 |
Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?
Topics: Anti-Inflammatory Agents; Chloroquine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; H | 2021 |
A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Tre | 2021 |
1 trial available for chloroquine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Effect of Chloroquine and Hydroxychloroquine on Cytokine Release Syndrome in Patients with COVID-19.
Topics: Adult; Antiviral Agents; Chloroquine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; Hy | 2021 |
4 other studies available for chloroquine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Efficacy of glucocorticoids, chloroquine and vitamin A on cytokine release syndrome: a network pharmacology study.
Topics: Chloroquine; Cytokine Release Syndrome; Drugs, Chinese Herbal; Glucocorticoids; Humans; Interleukin- | 2022 |
Thoughts on COVID-19 and autoimmune diseases.
Topics: Antibodies, Monoclonal, Humanized; Autoimmune Diseases; Azetidines; Betacoronavirus; Chloroquine; Co | 2020 |
COVID-19: an unexpected indication for anti-rheumatic therapies?
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Azetidines; Betacoronavirus; Ch | 2020 |
Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19.
Topics: Autophagy; Cachexia; Chloroquine; COVID-19 Drug Treatment; Cytokine Release Syndrome; Cytokines; Hum | 2021 |